cbdMDYCBD +0.75%38 EBIT per Share is $-0.34 as of Mar. 2026. GuruFocus rates YCBD with a GF Score™ of 38/100 and a GF Value™ of $0.16 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 811 Drug Manufacturers companies, cbdMD ranks better than 96.92% on this metric.
cbdMD's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.08.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.34.
During the past 3 years, the average EBIT per Share Growth Rate was 82.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 66.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for cbdMD's EBIT per Share or its related term are showing as below:
YCBD'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -131.2 Med: 32.4 Max: 82.7
Current: 82.7
During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of cbdMD was 82.70% per year. The lowest was -131.20% per year. And the median was 32.40% per year.
YCBD's 3-Year EBIT Growth Rate is ranked better than 96.92% of 811
companies
in the Drug Manufacturers industry
Industry Median: 7.8
vs YCBD: 82.70
cbdMD's EBIT for the
three
months ended in Mar. 2026 was $-0.80 Mil.
cbdMD (AMEX:YCBD) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
cbdMD EBIT per Share Related Terms
cbdMD EBIT per Share Historical Data
* Premium members only.
The historical data trend for cbdMD's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.34
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
cbdMD (YCBD) has a EBIT per Share of $-0.34 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on cbdMD and its competitors. According to the industry distribution chart, cbdMD ranks #25 out of 811 companies in the Drug Manufacturers industry, placing it in the top 3.1%.
Is cbdMD's EBIT per Share too high?
cbdMD's current EBIT per Share is $-0.34. Based on the distribution chart, cbdMD ranks #25 out of 811 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, cbdMD has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does cbdMD's EBIT per Share compare to AKAN and GELS?
According to the Drug Manufacturers industry distribution chart, cbdMD ranks #25 out of 811 companies for EBIT per Share. This places cbdMD in the top 3% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.80, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on cbdMD and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. cbdMD's current EBIT per Share is $-0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is cbdMD stock overvalued right now?
Based on GuruFocus' analysis, cbdMD (YCBD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.16, compared to a current price of $0.69 — trading 328.1% above its estimated fair value. The current EBIT per Share is $-0.34. cbdMD's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For cbdMD (YCBD), the current EBIT per Share is $-0.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is cbdMD (YCBD) Overvalued in 2026?
Based on GuruFocus' analysis, cbdMD stock appears to be overvalued.
The current stock price of $0.69 is trading 328.1% above its estimated GF Value™ of $0.16.
GuruFocus considers cbdMD to be Significantly Overvalued.
Key valuation signals for YCBD:
EBIT per Share: $-0.34
GF Value™: $0.16 vs. price of $0.69 (328.1% above fair value)
No single metric tells the full story. See the YCBD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
38GF Score
Get the complete analysis for YCBD
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
YCBD has been successfully added to your 
